Aim: Surgical treatment of splenic flexure cancer (SFC) still presents some debated issues, including the role of laparoscopic surgery. The literature is based on small single‐centre series, while randomized controlled studies comparing open and laparoscopic treatment for colon cancer exclude SFC. This study aimed to determine the role of laparoscopic surgery in the treatment of SFC, comparing short‐ and long‐term outcomes with open surgery.Method: This was an international multicentre retrospective cohort study that analysed patients from 10 tertiary referral centres. From a cohort of 641 cases, 484 patients with Stage I–III SFC submitted to elective surgery with curative intent were selected. After 1:1 propensity score matching, 130 patients in the laparoscopic group (LapGroup) were compared with 130 patients in the open surgery group (OpenGroup).Results: After propensity score matching, the two groups were comparable for demographic and clinical parameters. OpenGroup presented a higher incidence of overall (P = 0.02) and surgery‐related complications (P = 0.05) but a similar rate of severe complications (P = 0.75). Length of stay was notably shorter in the LapGroup (P = 0.001). Overall (P = 0.793) as well as cancer‐specific survival (P = 0.63) did not differ between the two groups.Conclusions: Elective laparoscopic surgery for Stage I–III SFC is feasible and associated with improved short‐term postoperative outcomes compared to open surgery. Moreover, laparoscopic surgery appears to provide excellent long‐term cancer outcomes.
3568 Background: The programmed death-1 (PD-1)/PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. PD-L1 was expressed on tumor cells (TCs) or tumor-infiltrating immune cells (ICs) in several malignancies. We previously reported that high PD-L1 expression on TCs and ICs were associated with poor and better prognosis in patients with stage IIIb colorectal cancer, respectively. We reported whether these findings were validated in patients with stage III colorectal cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) blocks specimens were obtained from the patients with stage III colorectal cancer who underwent surgical resection and adjuvant chemotherapy at our institution between January 2009 and July 2012. We excluded patients who received radiotherapy or chemoradiotherapy before surgery. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TCs and ICs. Specimens were scored as IHC low (L) or high (H), when < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Two hundred and thirty-five patients were included in this analysis. Median age was 63 years (range 32-84). One hundred and seventy-four and 61 patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The number of patients with PD-L1 expression on TCs/ICs (H/H, H/L, L/H, and L/L) was 0, 19, 36, and 180, respectively. The median follow-up time of this study was 52.9 months. Patients with high PD-L1 expression on TCs had significantly shorter disease-free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21-4.62; p = 0.012). Meanwhile, patients with high PD-L1 expression on ICs were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16-0.98; p = 0.046). Conclusions: High PD-L1 expression on TCs negatively affect the survival, whereas high PD-L1 expression on ICs is associated with favorable prognosis of patients with stage III colorectal cancer.
1 June 2024 in Annals of Gastroenterological Surgery
Background: Intensive localized therapy is promising for the treatment of rectal cancer. In Japan, chemoradiotherapy (CRT) and neoadjuvant chemotherapy (NAC) are used as preoperative treatments for this disease. Magnetic resonance imaging (MRI) is used to diagnose lateral pelvic node (LPN) metastases, but the changes in LPN findings on MRI following preoperative treatment are unclear. Furthermore, there may be patients in whom LPN dissection can be omitted after CRT/NAC.Methods: Patients who underwent total mesorectal excision with LPN dissection after CRT/NAC at 13 Japanese Society for Cancer of the Colon and Rectum member institutions between 2017 and 2019 were included. Changes in the short diameter of the LPNs after CRT/NAC and the reduction rate were examined.Results: A total of 101 LPNs were examined in 28 patients who received CRT and 228 in 47 patients who received NAC. Comparison of LPNs before and after CRT/NAC showed that most LPNs shrank after CRT but that the size reduction was variable after NAC. Although some LPNs with a short diameter of <5 mm showed residual metastasis, no metastases were observed in LPNs that were <5 mm in short diameter before and after CRT/NAC and did not shrink after treatment.Conclusion: Although the short diameter of LPNs was significantly reduced by both CRT and NAC, even LPNs with a short diameter of <5 mm could have residual metastases. However, dissection may be omitted for LPNs <5 mm in short diameter that do not shrink after preoperative CRT or NAC.
Total pelvic exenteration (TPE) is a radical surgical procedure indicated for advanced pelvic malignancies involving adjacent organs. The Hugo™ RAS system, a newly introduced alternative to existing robotic platforms, has not yet been reported for use in TPE for rectal cancer. We present the first known case of robotic-assisted TPE using the Hugo™ RAS system in a patient with locally advanced rectal cancer (LARC) invading the prostate. A 69-year-old male presented with mucous and bloody stools and was diagnosed with cT4b (prostate, levator ani muscle) N0M0 rectal cancer. Following neoadjuvant short-course radiotherapy (25 Gy in 5 fractions), robotic-assisted TPE was performed. Port placement was strategically modified to overlap with the planned colostomy and urostomy sites, minimizing abdominal wall trauma. Radical en bloc resection was performed, and pelvic reconstruction was achieved using a gluteus maximus musculocutaneous flap combined with a fascia lata autograft. Urinary reconstruction was achieved with a robotic intracorporeal Wallace-type ileal conduit. The total operative time was 17 hours and 56 minutes, with an estimated blood loss of 175 mL. The postoperative course was complicated by Clavien–Dindo grade Ⅲa paralytic ileus, which resolved with conservative management. The final pathology showed pT4b (prostate) N1a M0 disease with a negative circumferential resection margin (11 mm). At 9-month follow-up, no recurrence was observed. This case demonstrates the technical feasibility and safety of robotic-assisted TPE using the Hugo™ RAS system. Further clinical experience and long-term follow-up are necessary to establish its reproducibility and oncologic safety.